Handel Aytu BioScience, Inc. - AYTU CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.136 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.025457% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.003235% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 0.01 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Aytu Biopharma Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Nøglestatistikker
| Tidligere luk* | 1.736 |
| Åben* | 1.656 |
| 1-Års Ændring* | 208.38% |
| Dagens Spænd* | 1.637 - 1.697 |
| 52-Ugers Spænd | 1.40-16.19 |
| Gennemsnitlig Volumen (10 dage) | 53.76K |
| Gennemsnitlig Volumen (3 måneder) | 1.67M |
| Market Cap | 6.88M |
| P/E-forhold | -100.00K |
| Udestående aktier | 3.78M |
| Omsætning | 104.12M |
| EPS | -206.58 |
| Dividend (Udbytte %) | N/A |
| Beta | -0.37 |
| Næste indtjeningsopgørelse | Sep 25, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 1.736 | 0.139 | 8.70% | 1.597 | 1.736 | 1.587 |
| Jun 1, 2023 | 1.647 | 0.060 | 3.78% | 1.587 | 1.667 | 1.568 |
| May 31, 2023 | 1.618 | -0.038 | -2.29% | 1.656 | 1.657 | 1.568 |
| May 30, 2023 | 1.618 | -0.078 | -4.60% | 1.696 | 1.697 | 1.587 |
| May 26, 2023 | 1.627 | 0.000 | 0.00% | 1.627 | 1.805 | 1.617 |
| May 25, 2023 | 1.618 | -0.147 | -8.33% | 1.765 | 1.766 | 1.558 |
| May 24, 2023 | 1.746 | -0.029 | -1.63% | 1.775 | 1.815 | 1.696 |
| May 23, 2023 | 1.765 | -0.009 | -0.51% | 1.774 | 1.904 | 1.765 |
| May 22, 2023 | 1.874 | 0.020 | 1.08% | 1.854 | 1.934 | 1.824 |
| May 19, 2023 | 1.844 | 0.020 | 1.10% | 1.824 | 1.934 | 1.795 |
| May 18, 2023 | 1.835 | 0.020 | 1.10% | 1.815 | 1.854 | 1.775 |
| May 17, 2023 | 1.736 | 0.090 | 5.47% | 1.646 | 1.746 | 1.607 |
| May 16, 2023 | 1.677 | 0.001 | 0.06% | 1.676 | 1.795 | 1.666 |
| May 15, 2023 | 1.726 | 0.011 | 0.64% | 1.715 | 1.805 | 1.697 |
| May 12, 2023 | 1.776 | -0.246 | -12.17% | 2.022 | 2.022 | 1.726 |
| May 11, 2023 | 2.022 | -0.010 | -0.49% | 2.032 | 2.151 | 1.913 |
| May 10, 2023 | 2.002 | 0.060 | 3.09% | 1.942 | 2.092 | 1.804 |
| May 9, 2023 | 1.953 | 0.326 | 20.04% | 1.627 | 2.052 | 1.577 |
| May 8, 2023 | 1.667 | 0.208 | 14.26% | 1.459 | 1.697 | 1.459 |
| May 5, 2023 | 1.480 | 0.041 | 2.85% | 1.439 | 1.519 | 1.341 |
Aytu BioScience, Inc. Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| Monday, September 25, 2023 | ||
| Tid (UTC) (UTC) 20:00 | Land US
| Begivenhed Q4 2023 Aytu Biopharma Inc Earnings Release Q4 2023 Aytu Biopharma Inc Earnings ReleaseForecast -Previous - |
| Monday, November 13, 2023 | ||
| Tid (UTC) (UTC) 21:00 | Land US
| Begivenhed Q1 2024 Aytu Biopharma Inc Earnings Release Q1 2024 Aytu Biopharma Inc Earnings ReleaseForecast -Previous - |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total omsætning | 96.669 | 65.632 | 27.6321 | 7.32036 | 3.66012 |
| Omsætning | 96.669 | 65.632 | 27.6321 | 7.32036 | 3.66012 |
| Kost af omsætning, Total | 44.386 | 36.432 | 7.55303 | 2.20204 | 2.05054 |
| Bruttofortjeneste | 52.283 | 29.2 | 20.0791 | 5.11832 | 1.60958 |
| Totale Driftsudgifter | 208.061 | 126.071 | 38.6481 | 33.9975 | 17.0825 |
| Salgs/Generelle/Admin. Udgifter, Total | 69.88 | 55.808 | 34.8024 | 19.2396 | 17.7325 |
| Forskning & Udvikling | 14.439 | 5.623 | 1.72142 | 0.58907 | 0.1676 |
| Depreciation / Amortization | 4.067 | 6.009 | 4.49047 | 2.13626 | 1.55371 |
| Usædvanlig Udgift (Indkomst) | 75.289 | 22.199 | -9.91925 | 9.83055 | -4.42185 |
| Driftsindtægter | -111.392 | -60.439 | -11.016 | -26.6772 | -13.4224 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -0.862 | -2.05 | -2.60466 | -0.45472 | 3.2345 |
| Netto Indkomst Før Skat | -110.283 | -58.03 | -13.6207 | -27.1319 | -10.1879 |
| Netto Indkomst Efter Skat | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Netto Indkomst Før Ekstra Ting | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Netto Indkomst | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Fortyndet Netto Indkomst | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Fortyndet Vægtet Gennemsnit Aktier | 0.07349 | 0.83733 | 0.22596 | 0.03897 | 0.00333 |
| Fortyndet EPS Uden Ekstraordinære Ting | -1499.08 | -69.6126 | -60.2791 | -696.182 | -3061.23 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Fortyndet Normaliseret EPS | -833.202 | -52.3801 | -104.177 | -443.938 | -4389.91 |
| Totale Ekstraordinære Ting | 0 | ||||
| Andre, Netto | 1.971 | 4.459 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total omsætning | 22.733 | 26.279 | 27.655 | 27.448 | 24.199 |
| Omsætning | 22.733 | 26.279 | 27.655 | 27.448 | 24.199 |
| Kost af omsætning, Total | 9.99 | 8.986 | 9.623 | 12.606 | 11.513 |
| Bruttofortjeneste | 12.743 | 17.293 | 18.032 | 14.842 | 12.686 |
| Totale Driftsudgifter | 31.291 | 33.072 | 29.308 | 45.361 | 78.685 |
| Salgs/Generelle/Admin. Udgifter, Total | 19.981 | 18.578 | 17.424 | 17.396 | 17.358 |
| Forskning & Udvikling | 0.856 | 1.71 | 1.064 | 3.697 | 3.726 |
| Depreciation / Amortization | 1.198 | 1.198 | 1.197 | 0.853 | 1.061 |
| Usædvanlig Udgift (Indkomst) | 0 | 2.6 | 10.809 | 45.027 | |
| Driftsindtægter | -8.558 | -6.793 | -1.653 | -17.913 | -54.486 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 1.358 | 0.1 | 1.08 | -0.787 | -0.055 |
| Andre, Netto | -0.128 | 0.999 | 1.468 | ||
| Netto Indkomst Før Skat | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Netto Indkomst Efter Skat | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Netto Indkomst Før Ekstra Ting | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Netto Indkomst | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Fortyndet Netto Indkomst | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Fortyndet Vægtet Gennemsnit Aktier | 3.72678 | 3.1103 | 0.1259 | 0.08989 | 1.48449 |
| Fortyndet EPS Uden Ekstraordinære Ting | -1.93196 | -2.15188 | -5.56812 | -196.925 | -35.7516 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -1.93196 | -1.31595 | -5.56812 | -76.6739 | -5.42003 |
| Other Operating Expenses, Total | -0.734 |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 59.929 | 105.234 | 75.4226 | 15.4329 | 9.47029 |
| Likvider og Kortsigtede Investeringer | 19.36 | 49.649 | 48.0817 | 11.0442 | 7.01253 |
| Likvider & Lignende | 19.36 | 49.649 | 48.0817 | 11.0442 | 7.01253 |
| Kortsigtede Investeringer | |||||
| Totale Tilgodehavender, Netto | 21.712 | 28.176 | 5.63272 | 1.74079 | 0.57878 |
| Accounts Receivable - Trade, Net | 21.712 | 28.176 | 5.63272 | 1.74079 | 0.57878 |
| Total Inventory | 10.849 | 16.339 | 9.99944 | 1.44007 | 1.33897 |
| Prepaid Expenses | 7.375 | 9.78 | 5.71509 | 0.95778 | 0.44001 |
| Total Assets | 137.623 | 265.668 | 153.293 | 34.7214 | 21.0601 |
| Property/Plant/Equipment, Total - Net | 6.296 | 8.703 | 0.89261 | 0.20373 | 0.21868 |
| Goodwill, Net | 0 | 65.802 | 28.0904 | 0 | |
| Intangibles, Net | 70.632 | 85.464 | 48.8546 | 19.0826 | 11.366 |
| Other Long Term Assets, Total | 0.766 | 0.465 | 0.03298 | 0.0022 | 0.00509 |
| Total Current Liabilities | 64.442 | 109.438 | 28.7634 | 5.37258 | 3.39478 |
| Payable/Accrued | 9.468 | 8.689 | 0.959 | ||
| Accrued Expenses | 35.946 | 49.485 | 11.1046 | 1.99724 | 0.72656 |
| Notes Payable/Short Term Debt | 3.813 | 7.934 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 4.132 | 7.407 | 4.87523 | 1.07807 | 0.54855 |
| Total Liabilities | 91.531 | 128.1 | 58.2778 | 27.6336 | 7.63559 |
| Total Long Term Debt | 14.279 | 0.18 | 0 | 0 | 0 |
| Other Liabilities, Total | 12.81 | 18.482 | 29.5145 | 22.261 | 4.24081 |
| Total Equity | 46.092 | 137.568 | 95.0153 | 7.08782 | 13.4245 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0.00036 | 0 |
| Common Stock | 0.004 | 0.003 | 0.00126 | 0.00175 | 0.00018 |
| Additional Paid-In Capital | 334.56 | 315.864 | 215.024 | 113.475 | 92.6819 |
| Retained Earnings (Accumulated Deficit) | -288.472 | -178.299 | -120.01 | -106.39 | -79.2576 |
| Total Liabilities & Shareholders’ Equity | 137.623 | 265.668 | 153.293 | 34.7214 | 21.0601 |
| Total Common Shares Outstanding | 1.92894 | 1.37452 | 0.62919 | 0.08769 | 0.00897 |
| Other Current Assets, Total | 0.633 | 1.29 | 5.9936 | 0.25 | 0.1 |
| Accounts Payable | 10.987 | 19.255 | 11.8246 | 2.29727 | 2.11967 |
| Property/Plant/Equipment, Total - Gross | 8.717 | 9.715 | 1.37661 | 0.59973 | 0.75868 |
| Accumulated Depreciation, Total | -2.421 | -1.012 | -0.484 | -0.396 | -0.54 |
| Total Preferred Shares Outstanding | 0 | 0 | 3.59498 | ||
| Current Port. of LT Debt/Capital Leases | 0.096 | 16.668 | 0 | ||
| Capital Lease Obligations | 0.084 | 0.18 | 0 | ||
| Long Term Debt | 14.195 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 78.465 | 70.611 | 74.415 | 59.929 | 77.947 |
| Likvider og Kortsigtede Investeringer | 19.179 | 19.501 | 23.811 | 19.36 | 27.613 |
| Likvider & Lignende | 19.179 | 19.501 | 23.811 | 19.36 | 27.613 |
| Totale Tilgodehavender, Netto | 34.043 | 25.547 | 27.924 | 21.712 | 27.613 |
| Accounts Receivable - Trade, Net | 34.043 | 25.547 | 27.924 | 21.712 | 27.613 |
| Total Inventory | 13.637 | 12.95 | 12.871 | 10.849 | 13.891 |
| Prepaid Expenses | 10.429 | 11.989 | 9.024 | 7.375 | 7.942 |
| Other Current Assets, Total | 1.177 | 0.624 | 0.785 | 0.633 | 0.888 |
| Total Assets | 147.216 | 141.436 | 150 | 137.623 | 168.826 |
| Property/Plant/Equipment, Total - Net | 4.395 | 5.019 | 5.648 | 6.296 | 7.04 |
| Property/Plant/Equipment, Total - Gross | 7.779 | 8.083 | 8.384 | 8.717 | 8.78 |
| Accumulated Depreciation, Total | -3.384 | -3.064 | -2.736 | -2.421 | -1.74 |
| Goodwill, Net | 0 | 8.637 | |||
| Intangibles, Net | 63.464 | 64.985 | 69.108 | 70.632 | 74.428 |
| Other Long Term Assets, Total | 0.892 | 0.821 | 0.829 | 0.766 | 0.774 |
| Total Current Liabilities | 85.416 | 67.15 | 73.204 | 64.442 | 80.36 |
| Accounts Payable | 14.673 | 10.58 | 14.667 | 10.987 | 11.13 |
| Payable/Accrued | 10.287 | 9.137 | 8.08 | 9.468 | 12.058 |
| Accrued Expenses | 40.55 | 33.326 | 34.603 | 35.946 | 47.873 |
| Notes Payable/Short Term Debt | 10.403 | 7.429 | 8.087 | 3.813 | 3.385 |
| Current Port. of LT Debt/Capital Leases | 3.305 | 0.09 | 0.925 | 0.096 | 0.1 |
| Other Current Liabilities, Total | 6.198 | 6.588 | 6.842 | 4.132 | 5.814 |
| Total Liabilities | 106.304 | 95.619 | 96.094 | 91.531 | 107.682 |
| Total Long Term Debt | 11.386 | 14.533 | 13.56 | 14.279 | 14.167 |
| Long Term Debt | 11.371 | 14.494 | 13.498 | 14.195 | 14.061 |
| Capital Lease Obligations | 0.015 | 0.039 | 0.062 | 0.084 | 0.106 |
| Other Liabilities, Total | 9.502 | 13.936 | 9.33 | 12.81 | 13.155 |
| Total Equity | 40.912 | 45.817 | 53.906 | 46.092 | 61.144 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.00038 | 0.00034 | 0.006 | 0.004 | 0.003 |
| Additional Paid-In Capital | 342.584 | 340.289 | 345.253 | 334.56 | 331.912 |
| Retained Earnings (Accumulated Deficit) | -301.672 | -294.472 | -291.353 | -288.472 | -270.771 |
| Total Liabilities & Shareholders’ Equity | 147.216 | 141.436 | 150 | 137.623 | 168.826 |
| Total Common Shares Outstanding | 3.77951 | 3.38315 | 3.12147 | 1.92894 | 1.6678 |
| Total Preferred Shares Outstanding | |||||
| Other Equity, Total | -0.00038 | -0.00034 |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto indkomst/Startlinje | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Likvider Fra Driftsaktiviteter | -28.823 | -25.964 | -28.3739 | -13.8314 | -15.9403 |
| Likvider Fra Driftsaktiviteter | 10.251 | 9.201 | 6.24583 | 2.72707 | 2.59127 |
| Deferred Taxes | |||||
| Ikke-Likvide Ting | 81.962 | 21.443 | -8.38913 | 10.7837 | -7.62492 |
| Ændringer i Driftskapital | -10.863 | 1.681 | -12.6099 | -0.2102 | -0.71881 |
| Likvider fra Investeringsaktiviteter | -3.248 | -2.782 | -5.65577 | -1.06199 | -0.48429 |
| Kapitaludgifter | -2.341 | 0 | -0.05985 | -0.07471 | |
| Andre Investerings-Cash-Flow-Ting, Total | -3.248 | -0.441 | -5.65577 | -1.00214 | -0.40959 |
| Likvider fra Financieringsaktiviteter | 1.53 | 30.314 | 71.0687 | 19.0751 | 22.6596 |
| Financiering af Cash-Flow-Ting | -4.942 | -10.996 | -5.40415 | -1.47996 | -2.75752 |
| Udstedelse (Pensionering) af Aktier, Netto | 11.694 | 45.051 | 92.7217 | 15.555 | 25.4171 |
| Udstedelse (Pensionering) af Gæld, Netto | -5.222 | -3.741 | -16.2488 | 5 | |
| Netto Ændring i Likviditet | -30.541 | 1.568 | 37.0391 | 4.1817 | 6.23499 |
| Likvid Rente Betalt | 3.148 | 1.249 | 1.04028 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.594 | -7.394 | -2.881 | -110.173 | -92.472 |
| Cash From Operating Activities | -14.494 | -11.588 | -9.148 | -28.823 | -21.728 |
| Cash From Operating Activities | 6.699 | 4.505 | 2.328 | 10.251 | 8.005 |
| Non-Cash Items | 1.658 | 3.846 | 1.488 | 81.962 | 67.39 |
| Cash Interest Paid | 2.861 | 2.021 | 0.565 | 3.148 | 3.08 |
| Changes in Working Capital | -8.257 | -12.545 | -10.083 | -10.863 | -4.651 |
| Cash From Investing Activities | 0.038 | 0.037 | 0.042 | -3.248 | -3.207 |
| Other Investing Cash Flow Items, Total | 0.038 | 0.037 | 0.042 | -3.248 | -3.207 |
| Cash From Financing Activities | 14.275 | 11.692 | 13.557 | 1.53 | 2.647 |
| Financing Cash Flow Items | -5.254 | -3.497 | -1.107 | -4.942 | -4.429 |
| Issuance (Retirement) of Stock, Net | 13.012 | 11.573 | 10.416 | 11.694 | 12.7 |
| Issuance (Retirement) of Debt, Net | 6.517 | 3.616 | 4.248 | -5.222 | -5.624 |
| Net Change in Cash | -0.181 | 0.141 | 4.451 | -30.541 | -22.288 |
| Capital Expenditures |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | Hedge Fund | 7.1847 | 271595 | 0 | 2023-05-26 | LOW |
| Alyeska Investment Group, L.P. | Hedge Fund | 1.984 | 75000 | 0 | 2023-03-31 | |
| Brooke (Christopher) | Individual Investor | 1.5438 | 58357 | 58357 | 2022-11-15 | |
| Disbrow (Joshua R.) | Individual Investor | 1.5235 | 57591 | -3 | 2023-03-24 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.3127 | 49623 | -57416 | 2023-03-31 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.2503 | 47263 | 4379 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6365 | 24059 | -1 | 2023-03-31 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.5962 | 22537 | 2640 | 2023-03-31 | MED |
| Commonwealth Financial Network | Investment Advisor | 0.4137 | 15637 | 159 | 2023-03-31 | LOW |
| PGIM Quantitative Solutions LLC | Investment Advisor | 0.375 | 14176 | 5198 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3185 | 12039 | -2 | 2023-03-31 | LOW |
| Oki (Mark K) | Individual Investor | 0.2513 | 9500 | 0 | 2023-03-24 | LOW |
| Pyszczymuka (Greg) | Individual Investor | 0.2408 | 9103 | 5000 | 2022-12-19 | |
| Cantrell (Gary V.) | Individual Investor | 0.217 | 8204 | -2000 | 2022-12-21 | |
| Dockery (Carl C) | Individual Investor | 0.2157 | 8152 | -2 | 2023-03-24 | LOW |
| Liu (Vivian H) | Individual Investor | 0.1805 | 6825 | 0 | 2023-03-24 | HIGH |
| Ronald Blue Trust, Inc. | Investment Advisor | 0.1476 | 5579 | 5300 | 2023-03-31 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 0.1395 | 5273 | 5012 | 2023-03-31 | LOW |
| Tower Research Capital LLC | Hedge Fund | 0.0457 | 1726 | 113 | 2023-03-31 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 0.0228 | 861 | 0 | 2023-03-31 | MED |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group535K+
Handlende
87K+
Månedlkige, aktive klienter
$113M+
Månedlig investeringsvolumen
$64M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Aytu BioScience, Inc. Company profile
Om Aytu BioScience, Inc.
Aytu Biopharma, Inc. tidligere Aytu BioScience, Inc. er en specialiseret lægemiddelvirksomhed. Selskabet markedsfører en portefølje af receptpligtige produkter, der henvender sig til markederne for primær pleje og pædiatri. Selskabets primære receptpligtige produkter behandler ADHD (attention deficit hyperactivity disorder) og andre almindelige pædiatriske lidelser. Selskabet markedsfører ADHD-produkterne Adzenys XR-ODT (amfetamin), tabletter med forlænget oral frigivelse, Cotempla XR-ODT (methylphenidat), tabletter med forlænget oral frigivelse, og Adzenys-ER (amfetamin), oral suspension med forlænget oral frigivelse. Selskabets andre pædiatriske produkter omfatter Karbinal ER (carbinoxaminmaleat), en suspension med forlænget frigivelse af carbinoxamin (antihistamin) til behandling af en lang række allergiske tilstande, og Poly-Vi-Flor og Tri-Vi-Flor, to komplementære fluoridbaserede receptpligtige vitaminproduktserier, der indeholder kombinationer af fluorid og vitaminer i formuleringer til spædbørn og børn med fluoridmangel.
| Industry: | Pharmaceuticals (NEC) |
373 Inverness Pkwy Ste 206
80112
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 535.000+ handlende over hele verden, der valgte at handle hos Capital.com